U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma

On March 29, 2011, the U.S. Food and Drug Administration approved peginterferon alfa-2b (PEG-IFN) (Sylatron™; Schering Corporation, Kenilworth, NJ) for the adjuvant treatment of melanoma patients with microscopic or gross nodal involvement following definitive surgical resection including complete l...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Herndon, Thomas M., Demko, Suzanne G., Jiang, Xiaoping, He, Kun, Gootenberg, Joseph E., Cohen, Martin H., Keegan, Patricia, Pazdur, Richard
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2012
Teme:
Regulatory Issues: FDA
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3481898/
https://ncbi.nlm.nih.gov/pubmed/23002124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0123
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki